Loading organizations...
MBrace Therapeutics is a clinical stage company focused on translating innovative antibody-drug conjugate (ADC) discovery into transformative therapies for cancer patients. They identify new cancer targets for their products, including lead ADC products currently in clinical trials.
MBrace Therapeutics has raised $110.0M across 2 funding rounds.
MBrace Therapeutics has raised $110.0M in total across 2 funding rounds.
MBrace Therapeutics has raised $110.0M in total across 2 funding rounds.
MBrace Therapeutics's investors include Carolyn Ng, Advanced Technology Ventures, Novo Ventures, RA Capital, Venrock, Bob Moore, Monal Mehta, Cowen Healthcare Investments.
MBrace Therapeutics has raised $110.0M across 2 funding rounds. Most recently, it raised $85.0M Series B in November 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2023 | $85M Series B | Carolyn NG | Advanced Technology Ventures, Novo Ventures, RA Capital, Venrock, BOB Moore, Monal Mehta, Cowen Healthcare Investments | Announced |
| Dec 1, 2020 | $25M Series A | — | Advanced Technology Ventures, Novo Ventures, RA Capital, Venrock | Announced |
MBrace Therapeutics is a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for cancer treatment, targeting novel oncology markers to selectively kill cancer cells while sparing healthy tissue.[1][2][3] Its lead candidate, MBRC-101, is an ADC against the EphA5 receptor tyrosine kinase, addressing hard-to-treat solid tumors like breast, NSCLC, colorectal, gastric, and pancreatic cancers; the company serves patients with advanced metastatic solid tumors refractory to standard care.[1][5] Backed by $110 million in total funding—including an $85 million Series B in November 2023 led by TPG—MBrace is advancing a Phase 1/1b trial (NCT06014658) for MBRC-101, with patient dosing initiated and preclinical data showing complete tumor regression in models.[3][4][5] The proprietary SPARTA platform (Selection of Phage-displayed Accessible Recombinant Targeted Antibodies) enables rapid discovery of tumor-specific, internalizing antibodies for ADCs, driving growth toward commercialization.[1][2][3]
MBrace emerged from stealth in November 2023 with its $85 million Series B, building on technology pioneered by its founders at Rutgers, The State University of New Jersey, including the SPARTA platform in-licensed via sponsored research with Rutgers Cancer Institute.[3][5] Leadership includes Isan Chen, M.D., president and CEO, who has guided the push into clinical trials, and Jay, a key executive with prior experience as Vice President, Head of BD&A at AbbVie (2016-2025), where he led major deals like the $63 billion Allergan acquisition and strategies in oncology.[6] The idea stemmed from unmet needs in cancer therapy, leveraging SPARTA's *in vivo* phage-display to identify accessible, cancer-specific targets previously technically challenging; early traction included extensive preclinical validation on targets like EphA5 and GRP78, culminating in MBRC-101's first-in-human trial launch by year-end 2023.[1][2][3]
MBrace rides the ADC boom in oncology, where targeted therapies like ADCs (e.g., Tecentriq, Lynparza analogs) are transforming care by improving efficacy and minimizing toxicity amid rising cancer prevalence.[1][2] Timing aligns with ADC market expansion—validated by investor confidence and clinical milestones—fueled by advances in conjugation (e.g., ThioBridge) and biologics platforms addressing resistance in solid tumors.[5] Market forces favoring MBrace include regulatory tailwinds for precision oncology, demand for novel targets beyond PD-L1/PARP, and biotech funding recovery for high-impact modalities; it influences the ecosystem by validating SPARTA for broader ADC innovation, potentially expanding accessible targets and partnering with CROs like Abzena/Rutgers.[1][3][5]
MBrace is poised for Phase 1 data readouts from MBRC-101 in 2025-2026, with expansion cohorts targeting EphA5-high cancers and pipeline advancement via SPARTA.[3][4][5] ADC evolution—toward multi-specifics, better payloads, and combo regimens—will shape its path, amplified by oncology M&A trends and its AbbVie-honed BD expertise.[6] Influence may grow through partnerships or buyouts, redefining targeted cancer care as this clinical-stage player delivers on its stealth-to-series promise.[1][3]
